Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
2269.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
+52%
0.19
vs 0.13
Q4.20
+66%
0.26
vs 0.16
Q2.21
+158%
0.5
vs 0.19
Q4.21
+61%
0.43
vs 0.26
Q2.22
+35%
0.68
vs 0.5
Q4.22
+15%
0.49
vs 0.43
Q2.23
-17%
0.56
vs 0.68
Q4.23
-41%
0.29
vs 0.49
Q2.24
-33%
0.38
vs 0.56
Q4.24
-17%
0.24
vs 0.29
Sales Growth
YoY
Current
Estimates
Q2.20
+21%
1.9B vs 1.6B
Q4.20
+54%
3.7B vs 2.4B
Q2.21
+127%
4.4B vs 1.9B
Q4.21
+60%
5.9B vs 3.7B
Q2.22
+64%
7.2B vs 4.4B
Q4.22
+37%
8.1B vs 5.9B
Q2.23
+18%
8.5B vs 7.2B
Q4.23
+6%
8.5B vs 8.1B
Q2.24
+1%
8.6B vs 8.5B
Q4.24
+18%
10.1B vs 8.5B
Return on Equity
QoQ
Q2.21
+6%
0.06
vs 0.05
Q4.21
+5%
0.05
vs 0.06
Q2.22
+7%
0.07
vs 0.05
Q4.22
+5%
0.05
vs 0.07
Q2.23
+6%
0.06
vs 0.05
Q4.23
+3%
0.03
vs 0.06
Q2.24
+4%
0.04
vs 0.03
Q4.24
+4%
0.04
vs 0.04
Institutionnal Ownership
QoQ
Q1.19
1
1
vs NA
NA
Q2.19
1
1
vs 1
NA
Q3.19
1
1
vs 1
NA
Q4.19
1
1
vs 1
NA
Q1.20
1
1
vs 1
NA
Q2.20
1
1
vs 1
NA
Q3.20
1
1
vs 1
NA
headlinesoftoday.com
20 hours ago
headlinesoftoday.com
22 hours ago
Quote Panel
Key Metrics
Relative Strength
2269.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
130%2025-Revenue
99%2025-EPS
126%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
HKSE
0.40 ( 1.55%)
Pre-market NaN$0.00 (0.00%)
Relative Strenght
Volume Buzz
-32%
Earning Acce
Yes
Dist 52w H.
11%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 2269.HK compares to sector?